Z A1AT Secretion Inducer for Correct Protein Folding in AATD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for alpha-1-antitrypsin deficiency (AATD) are inadequate in addressing the misfolding and accumulation of Z alpha-1-antitrypsin (Z A1AT) proteins, leading to respiratory and liver complications such as COPD and cirrhosis, with augmentation therapy being the primary approach for lung manifestations and liver issues managed through steroids and transplantation.
Innovation Solution
The use of 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid to induce the secretion of correctly folded Z A1AT, thereby increasing its levels and mitigating the effects of AATD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If augmentation therapy using A1AT concentrates is used, then blood levels of A1AT are increased, but the treatment does not address the underlying protein folding and secretion defects
Solution Approach 1:
The compound acts on hepatocytes to improve Z-A1AT folding and secretion before the protein enters the bloodstream, addressing the root cause rather than just supplementing the protein later. This preliminary intervention at the cellular level enables endogenous production of functional A1AT.
Solution Approach 2:
The treatment stimulates the patient's own liver cells to produce and secrete functional A1AT, rather than relying on external infusions. The hepatocytes are empowered to correct their own folding defects and naturally secrete the protein into the bloodstream.
2Object-generated harmful factors
If compounds are designed to inhibit Z A1AT polymerisation, then polymer formation is reduced, but correctly folded and secreted A1AT levels are not sufficiently increased
Solution Approach 1:
The compound modifies the physicochemical environment within hepatocytes, altering parameters such as pH, redox state, or chaperone activity to promote correct Z-A1AT folding. This parameter change prevents misfolding that would otherwise lead to polymerization.
Solution Approach 2:
The compound acts as a molecular chaperone or folding assistant, mediating the interaction between Z-A1AT and the cellular folding machinery. It facilitates proper conformational changes and prevents aggregation during the folding process.
3Manufacturing precision
If compounds aim to improve Z A1AT folding, then secretion may be enhanced, but the effectiveness in increasing active A1AT levels is insufficient
Solution Approach 1:
The compound establishes continuous improvement of folding efficiency over time, with sustained enhancement of both folding accuracy and secretion rates. This continuous action leads to progressively higher levels of active A1AT in the bloodstream.
Solution Approach 2:
The compound simultaneously addresses multiple aspects of protein quality control: folding accuracy, secretion efficiency, and prevention of degradation. By merging these functions into a single therapeutic agent, it achieves comprehensive improvement in active A1AT levels.
Data Source
AI summary
The invention relates to 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid, compositions thereof, and uses of either, for example in the treatment of α1-antitrypsin deficiency (A1AD or AATD).